A 49-year-old woman with a 12-year history of obesity and type 2 diabetes presents to her primary care physician for a routine follow-up. Her current medications include metformin 1000 mg twice daily, but her glycemic control remains suboptimal. Her BMI is 34 kg/m², blood pressure is 128/82 mmHg, and fasting plasma glucose is 187 mg/dL. Her most recent HbA1c is 8.4%. Physical examination reveals acanthosis nigricans at the nape of the neck and mild central adiposity. She expresses strong interest in a medication that improves glycemic control while also promoting weight loss. Her physician prescribes a once-weekly injectable drug that increases glucose-dependent insulin secretion, decreases glucagon release, and delays gastric emptying. Which of the following medications was most likely prescribed?

1. A)Insulin glargine
2. B)Miglitol
3. C)Glyburide
4. D)SemaglutideGABARITO
5. E)Metformin